We describe a patient who suffered cardiovascular collapse and bronchospasm following induction of anaesthesia. This was demonstrated by subsequent intradermal testing to be the result of anaphylaxis to the new nondepolarizing muscle relaxant mivacurium. To our knowledge, anaphylaxis to mivacurium has not been previously described.
We describe a patient who suffered cardiovascular collapse and bronchospasm following induction of anaesthesia. This was demonstrated by subsequent intradermal testing to be the result of anaphylaxis to the new nondepolarizing muscle relaxant mivacurium. To our knowledge, anaphylaxis to mivacurium has not been previously described.
CASE HISTORY
A 49 kg twelve-year-old boy presented with right iliac fossa pain and was diagnosed as having appendicitis with perforation. Past medical history included an apparently uneventful anaesthetic for tonsillectomy at another hospital. The patient received papaveretum, hyoscine, thiopentone, suxamethonium and halothane at that time. He did not receive a nondepolarizing muscle relaxant. On another occasion, several years previously, he had experienced an isolated episode of wheeze, although no diagnosis of asthma had been made. He was taking no medications.
It was elected to perform a modified rapid sequence induction including pre-oxygenation and application of cricoid pressure. Fentanyl 1.0 µg.kg -1 and metoclopramide 0.1 mg.kg -1 were given via an intravenous crystalloid infusion running through a 22 gauge cannula in a forearm vein. Subsequently propofol 2.6 mg.kg -1 containing lignocaine 1.0 mg/ml was given followed by mivacurium 0.2 mg.kg -1 . Immediately after induction the patient coughed, and perioral pallor was seen. The patient's lungs were noted to be difficult to inflate at this time, and the capnograph expiratory waveform showed a markedly reduced slope with a fall in measured end-tidal carbon dioxide tension. The trachea was intubated approximately 90 seconds after induction. Intubation was straightforward, with a clear pharynx. After intubation, peak airway pressure was measured as 55 cm water. Systolic blood pressure was measured noninvasively as 65 mmHg. The lungs were ventilated with 100% oxygen and halothane 1%. A bolus dose of adrenaline 2 µg.kg -1 IV was followed by a fall in peak airway pressure to 35 cm water and a rise in systolic blood pressure to 105 mmHg. At this stage a 16 gauge intravenous cannula was inserted into a large contralateral arm vein and a total volume of three litres of crystalloid (Plasmalyte) was given over 45 minutes. Although the blood pressure stabilized, repeated boluses of adrenaline to a total of 14.3 µg.kg -1 were required to maintain inflation pressures in the range 30 to 40 cm H 2 O.
Because of the surgical diagnosis it was decided to proceed with surgery, having obtained relative haemodynamic and cardiovascular stability. However, skin incision was accompanied by the development of multifocal ectopic beats and isoflurane 2% was used in place of halothane. Further doses of fentanyl to a total of 8 µg.kg -1 were given for analgesia. Salbutamol 4 µg.kg -1 and 2 µg.kg -1 were used in addition to adrenaline to reduce bronchospasm. Chlorpheniramine 0.2 mg.kg -1 and hydrocortisone 2 mg.kg -1 were given by intravenous injection towards the end of surgery. Continuous infusion of adrenaline was commenced at a rate of 0.3 µg.kg -1 .min -1 , and reduced after 30 minutes to a rate of 0.2 µg.kg -1 . At the end of surgery, the patient's blood pressure was 124/75 mmHg, heart rate 110 bpm, oxygen saturation 100% (the patient did not experience desaturation at any time), and end-tidal carbon dioxide tension 40 mmHg.
Still intubated and ventilated, the patient was transferred electively to the paediatric intensive care unit postoperatively, where he was weaned from the adrenaline infusion over the following hour. The patient was extubated uneventfully and was discharged to the ward the following day.
Blood was drawn in theatre for serum tryptaseestimation 1 performed using a solid phase immunoradiometric assay (RIACT-Pharmacia) and the patient referred for skin testing.
Diagnosis
Serum tryptase levels rise following anaphylaxis as the result of tryptase release after mast cell degranulation 2 . The tryptase assay taken within half an hour of the reaction gave a result of 0.9 U/l. This was the only sample of blood taken for tryptase assay in this patient. A normal result is considered to be 0.5 U/l or lower, starting to rise at between half and one hour following the onset of anaphylaxis. It is probable that the sample was taken as the level was starting to rise, and in fact was considerably higher a few hours later. It is recommended that tryptase assay is performed as soon as possible after the collapse and then periodically during the subsequent 24 hours 3 .
Eight weeks after the patient's discharge from hospital he was tested intradermally to the agents given during this anaesthetic (fentanyl, metoclopramide, propofol and mivacurium) and in addition thiopentone, suxamethonium, d-tubocurarine, pancuronium, atracurium, vecuronium, papaveretum and hyoscine. The methodology used was that previously described by Fisher 4 . For most of the drugs, commercial solutions were diluted 1:1000 by volume with saline. The exceptions were propofol, thiopentone and fentanyl (1:100 dilution) and papaveretum and d-tubocurarine (1:10,000). Using normal saline as a control to test for dermographism, 0.02 ml of each solution was injected intradermally into a premarked area of the forearm via a 25 gauge needle. A 10% solution of histamine inoculated via a skin scratch was used as a positive control. At 30 minutes the only wheal greater than 10 mm diameter was due to mivacurium (15 mm) and this was accompanied by a 145 mm flare which was absent for all of the other test solutions. The anaesthetist overseeing the Department of Immunology's anaesthetic allergy testing service considered the results were indicative of allergy to mivacurium.
DISCUSSION
Anaphylaxis to nondepolarizing muscle relaxants is well described 3, 5, 6, 7 with 59 to 70% of reactions being due to these drugs in some series of anaestheticrelated events 5, 7 . The fact that our patient had no previous exposure to mivacurium is typical of many reactors to muscle relaxants 5 .
Histamine release associated with falls in arterial pressure is known to occur following intravenous injection of mivacurium, particularly if injection is rapid 8 . This might be expected from the structural similarities between mivacurium and the other benzylisoquinolinium compound atracurium, also a potent cause of histamine release. Cutaneous flushing, an indicator of histamine release, has been reported in approximately 15 to 20% of adult patients receiving the recommended intubating dose of mivacurium 8, 9 . However mivacurium is unlikely to give rise to higher plasma levels of histamine than atracurium for an equipotent dose given at a similar rate. Studies have not compared the two drugs directly, but in separate studies by the same investigators, increases in plasma histamine were greater with atracurium when equipotent doses of the drugs were used, although speed of injection was faster in the atracurium study 8, 10 . Speed of injection has consistently been shown to be proportional to the rise in plasma histamine for a given dose of drug 8, 11 . Despite the known propensity of mivacurium to release histamine, cardiovascular collapse and bronchospasm of the degree that was seen in this patient was not expected from the results of early work on mivacurium. Nor might it be expected from epidemiological data which shows a poor association between the minor histamine release of a drug and the frequency of anaphylaxis associated with its use 3 . The fact that this patient required prolonged high dose adrenaline suggested clinically that the reaction was not simply the result of minor histamine release.
